Equity
€518,959 ▼ 23.6%
ENDODERM paid out €359,194 in dividends. That is 180% of the 2025 profit.
ENDODERM
Lifetime
10 annual accounts with figures on one time axispeak €354,931 (2025)
€354,931▲ 168%
peak €199,187 (2025)
€199,187▲ 391%
peak €779,187 (2023)
€518,959▼ 23.6%
€677,461▲ 58.5%
Board2 names since 2016
2 directors and 1 other
Documentsfilings and deeds
23-07-20268 days before the deadline
2025abbreviated format
Turnover from €582,831 to €744,092Gross margin from €132,327 to €354,931Result from €40,577 to €199,187Dividend €359,194Equity from €678,966 to €518,959Debts from €427,417 to €677,461
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 17,811 companies had the same profile as ENDODERM has now. Each dot stands for 45 companies, two years later.
96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,811 companies, not a prediction for ENDODERM. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director
Director
- 50 sharesdeed of 03-07-2023
- 50 sharesdeed of 03-07-2023
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0655942209
Appointments: (director) and (director)
holds 50 shares · holds 50 shares · Legal-form conversion: from private limited company (pre-2019) to private limited company · General meeting of 28-06-2023 · Gazette deed
Reappointments: (director) and (director)
General meeting of 01-06-2022 · Gazette deed
Director in office: (manager)
Director in office: (manager) · General meeting of 20-12-2016 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ENDODERM Pont-à-Celles | €1.2m | €354,931 | 43.4% | - |
| S.SHAHSAVARI Woluwe-Saint-Pierre | €1.1m | €343,981 | 1.6% | - |
| Dr. Veerle Decuypere, cardioloog Bruges | €1.2m | €355,467 | 82.1% | - |
| DAN-CHABANSKI Uccle | €1.1m | €350,604 | 23.5% | - |
| DR. TIMUR ISSAEV, ANESTHESIE Lier | €1.2m | €342,142 | 47.2% | - |
| DOKTER PETER VORLAT Pelt | €1.1m | €335,191 | 49.3% | - |
| Hypatia Kampenhout | €1.2m | €405,999 | 69.2% | - |
These companies have the same main activity as ENDODERM: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.1m and €1.2m, founded between 2016 and 2017.
Official details
Source: KBO- Status
- Active since 06-06-2016Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.254.101.1436230 Pont-à-Celles, since 06-06-2016
- Financial year end
- 31 December
- Peppol
- Reachable since 28-02-2026
Annual accounts 2025
- €1.2m▲ 8.1%
- Filing
- Filed on 23-07-2026, 8 days before the end of the filing period
Insights on ENDODERM
ENDODERM files the abbreviated format. That format states no turnover. The gross margin rose from €79,419 in 2016 to €354,931 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ENDODERM
- What is the company number of ENDODERM?
- The company number of ENDODERM is 0655.942.209. The VAT number is the same number with BE in front: BE 0655.942.209.
- Where is ENDODERM based?
- The registered office is at Rue de Seneffe 3, 6230 Pont-à-Celles.Company details
- What does ENDODERM do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of ENDODERM?
- ENDODERM is a private limited company (BV).
- When was ENDODERM founded?
- ENDODERM was founded on 06-06-2016.
- Is ENDODERM still active?
- Yes, ENDODERM is an active enterprise in the KBO register.
- What is the turnover of ENDODERM?
- The turnover of ENDODERM was €744,092 in financial year 2025, according to the filed annual accounts.Financials
- Is ENDODERM profitable?
- In financial year 2025, ENDODERM made a profit of €199,187.
- Where can I find the annual accounts of ENDODERM?
- ENDODERM filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ENDODERM due?
- ENDODERM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.